Laurus Labs stock
Price history
+132.46% over the period1 year: from ₹987.10 (November 20, 2025) to ₹2,294.60 (November 20, 2026), +132.46%.
Show chart data
Closing prices adjusted for splits: the last close of each month.
| Date | Close |
|---|---|
| November 20, 2026 | ₹2,294.60 |
| October 30, 2026 | ₹2,405.50 |
| September 30, 2026 | ₹1,980.00 |
| August 31, 2026 | ₹1,915.00 |
| July 31, 2026 | ₹1,816.20 |
| June 30, 2026 | ₹1,517.40 |
| May 29, 2026 | ₹1,362.00 |
| April 30, 2026 | ₹1,100.95 |
| March 30, 2026 | ₹992.70 |
| February 27, 2026 | ₹1,075.80 |
| January 30, 2026 | ₹965.00 |
| December 31, 2025 | ₹1,108.00 |
| November 28, 2025 | ₹1,031.35 |
| November 20, 2025 | ₹987.10 |
At a glance
The company
Manufactures medicines, active pharmaceutical ingredients and recombinant proteins for global pharmaceutical markets
Latest results
Quarter to September 30, 2026 · EPS ₹8.20 (estimate ₹6.66)
Next event
TickerLandia's take on Laurus Labs
- Pricier than usual relative to earnings: P/E on the latest fiscal year 139 vs a median of 35 over its last 10 fiscal years.
- Pricier than similar companies: trailing 12-month P/E 98 vs 29 (+241%) in a group of 11.
- Strong point: Market momentum (99/100 in its group). Weak point: Dividend (16/100).
Analysis calculated by TickerLandia from financial statements and prices, with public rules. Not investment advice. How we analyse stocks
Where the price stands
−7.77% from the 52-week high
Analysts · 15 analysts
Average target₹2,156.29−6.03% vs. price
Buy 8 · Hold 3 · Sell 4 · Hold
TickerLandia Fingerprint: Laurus Labs
Compared with similar companies: very strong momentum, very high price, and very low dividend.
Financials and price compared with 39 companies in the drug manufacturers - specialty & generic industry, worldwide. Momentum and risk compared with 1,074 Asia-Pacific stocks.
Pricevery high96
How much it costs relative to what it produces.
Metric Value Position in group EV/EBITDA 56.1 96 Forward P/E 68.4 96 Price/book 21.6 99 Price/sales 16.7 93 P/E (trailing 12 months) 97.8 96 Profitabilityhigh68
How much it earns on revenue and capital.
Metric Value Position in group ROE 24.0% 91 Operating margin 24.1% 65 ROA 11.3% 86 Gross margin 60.4% 32 Net margin 17.1% 65 Earnings stabilitylow40
How steady its margins were over the last five annual reports.
Metric Value Position in group Margin variabilitycounts in reverse: lower means more earnings stability 6.8% 17 Loss-making yearscounts in reverse: lower means more earnings stability 0 of 5 annual reports 63 Growthhigh67
How fast revenue and earnings are growing.
Metric Value Position in group Average revenue growth (3 years) +4.09% 30 Revenue growth (year over year) +33.40% 82 Earnings growth (year over year) +126.00% 87 Financial strengthlow37
How well it would weather a hard period: debt, liquidity, interest.
Metric Value Position in group Current ratio 1.31 24 Net debt/EBITDAcounts in reverse: lower means more financial strength 0.51 50 Interest coverage 8.07 32 Debt/equitycounts in reverse: lower means more financial strength 0.42 42 Dividendvery low16
How much it returns to shareholders, and for how long.
Metric Value Position in group Consecutive dividend years at least 10 years 38 Dividend yield 0.1% 2 Payout ratio 8.9% 8 Market momentumvery strong99
How the stock has moved compared with the market.
Metric Value Position in group 1-year return +132.46% 98 Distance from 200-day average +47.28% 100 Risklow29
How much the price swings.
Metric Value Position in group Volatility (60 days) 37.5% 51 Maximum drawdown (12 months) 16.3% 8
Position in the group from 0 to 100 (100 = highest value): it describes, it does not rate. Tap a row for the metrics. Calculated on November 22, 2026. An indicator calculated by TickerLandia from financial statements and market data. How it is calculated
Valuation
Laurus Labs is pricier than in the past and pricier than similar companies
On the latest fiscal year's earnings (2026), Laurus Labs's P/E today is 139.5, above the median of its last 10 fiscal years (35.2; between 13.6 and 132.1 from 2017 to 2026). Laurus Labs's P/E (trailing 12 months): 97.8, +241% against the median of a group of 11 similar companies (28.7).
Compared with 11 similar companies
| Metric | Laurus Labs | Position in the group | Band |
|---|---|---|---|
| P/E (trailing 12 months) | 97.8 | High | |
| Forward P/E | 68.4 | High | |
| Operating margin | 24.1% | Middle | |
| ROE | 24.0% | High | |
| Debt/equity | 0.42 | High |
P/E at fiscal year end; today on the latest fiscal year's earnings. Grey band: the middle half of the group; tick: the median; dot: Laurus Labs. All multiples and dividends
TickerLandia analysisHow it is calculated
The financials
The business in numbers
Revenue
₹22.06B
Latest quarter · Q3 2026
Net income
₹4.41B
Latest quarter · Q3 2026
Quarterly net margin
20.0%
Latest quarter · Q3 2026
Numbers and valuation
Full valuation- Market cap
- ₹1.31T
- P/E
- 97.8
- EPS
- ₹24.78
- Volume
- 2.28M
- Daily trading
- €68.26M
- Dividend yield
- 0.10%
- Last ex-dividend on November 6, 2026
How Laurus Labs is changing
All resultsRevenue grew 7.2% a year on average over the last 5 years
Operating margin fell from 21.4% to 19.1%
Less cash than profit: free cash flow equal to 36% of net income
Returns
Laurus Labs returns with dividends
₹1,000 invested in Laurus Labs 5 years ago, on November 22, 2021, would be worth ₹4,931 today with dividends reinvested: +393.15% in total, +37.65% per year. On price alone it would be ₹4,863 (+386.30%).
| Period | Laurus Labs | ₹1,000 becomes |
|---|---|---|
| 1 month | +14.02% | ₹1,140 |
| 6 months | +68.58% | ₹1,686 |
| Year to date | +107.09% | ₹2,071 |
| 1 year | +132.79% | ₹2,328 |
| 3 years | +526.78% | ₹6,268 |
| 5 years | +393.15% | ₹4,931 |
From 1 year up with dividends reinvested, before taxes; under a year price only. Calculate your investment
The chart in detail
Laurus Labs: technical analysis
Laurus Labs is in an uptrend: the price is above its 50- and 200-session moving averages, and the 200-session average is rising. The price is 6.5% below its all-time closing high (₹2,454.00, November 9, 2026).
- Trend
- Upward
- RSI (14 sessions)
- 54
- Between 30 and 70
- vs 200-session average
- +47.28%
Support and resistance
Price areas where Laurus Labs has stopped several times in the last year. They describe the chart; they are not forecasts.
- No resistance above: the price is near the highs of the year
- Last price₹2,294.60
- Support₹1,944.87−15.24%3 touches, last on October 23, 2026
- Support₹1,867.15−18.63%2 touches, last on September 16, 2026
- Support₹1,452.60−36.69%2 touches, last on July 8, 2026
Volatility and risk
- Volatility (60 sessions, annualised)
- 37.5%
- Largest fall in the last year
- −16.27%
Close of November 20, 2026. Descriptive data calculated on daily prices: it describes the chart and is not investment advice. Beta and volatility describe the last year and can change a lot from one year to the next. How we calculate it
Laurus Labs: seasonality
Average monthly price change over 10 years
Over the last 10 years, the strongest month for Laurus Labs has been July: +12.35% on average, positive in 5 years out of 10. The weakest has been January: −3.72% on average, positive in 1 years out of 10. November, the current month, has been positive in 4 years out of 9 (+2.61% on average).
Show chart data
| Month | Average | Median | Positive years |
|---|---|---|---|
| January | −3.72% | −3.97% | 1 of 10 |
| February | +1.13% | +3.30% | 6 of 10 |
| March | +0.46% | −1.07% | 5 of 10 |
| April | +10.75% | +3.34% | 7 of 10 |
| May | +2.64% | −0.89% | 5 of 10 |
| June | +6.55% | +9.16% | 7 of 10 |
| July | +12.35% | +4.52% | 5 of 10 |
| August | +3.96% | +2.63% | 6 of 10 |
| September | +1.57% | −1.35% | 3 of 10 |
| October | −0.05% | +2.37% | 5 of 10 |
| November | +2.61% | −0.80% | 4 of 9 |
| December | +4.32% | +5.95% | 7 of 9 |
Price change only, dividends excluded. Past seasonality does not predict future moves.
The company
Laurus Labs and its competitors
Generic APIs and solid oral drug products for anti-retroviral treatments open the offering of Laurus Labs Limited, which manufactures and sells medicines and active pharmaceutical ingredients in India and internationally through its subsidiaries. Its range extends to anti-diabetic, cardiovascular, anti-asthma, ophthalmology, oncology and gastroenterology products, supplied as intermediates and finished dosages. The group also develops recombinant proteins and cell-culture media supplements free of animal-origin materials, provides drug substance, drug product and biologics development services, and offers rare disease therapeutics.
- Headquarters
- Hyderabad, India
- Employees
- 7,059
- Founded
- 2005
- Chief executive
- Satyanarayana Chava
| Company | Market cap | Operating margin | P/E (trailing 12 months) | 6 months |
|---|---|---|---|---|
| Laurus LabsLAURUSLABS | $14.13B | 24.1% | 97.8 | +68.58% |
| Yunnan Baiyao Group000538 | $15.07B | 11.2% | 19.4 | +11.07% |
| Zydus LifesciencesZYDUSLIFE | $12.92B | 17.2% | 28.7 | +15.29% |
| PharmaEssentia6446 | $15.94B | 38.4% | 74.1 | +54.65% |
| CiplaCIPLA | $12.34B | 13.0% | 39.5 | +1.11% |
| Shionogi4507 | $16.75B | 31.6% | 11.2 | +2.83% |
Same industry or related industries, similar size. Compare Laurus Labs with its competitors · Full profile
